Latest from Cleveland Clinic

Neoadjuvant stereotactic radiosurgery has gained interest. This approach allows for easier target delineation; a smaller margin of normal brain parenchymal receiving the radiosurgery dose, which may decrease toxicity; and the potential to reduce the risk of leptomeningeal disease by sterilizing the tumor margin preoperatively.
Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.
The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.
Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.
Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.
Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.
A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.
Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.
Publication Bottom Border
Border Publication